Baykar Expands European Footprint with Acquisition of Piaggio Aerospace

01-07-2025


In a significant move that underscores the growing importance of unmanned aerial systems (UAS) in global defense and aerospace sectors, Turkish company Baykar has finalized its acquisition of Italy's Piaggio Aerospace. This strategic acquisition, completed in the presence of key Italian government officials and Baykar's leadership, marks a pivotal moment for both companies. The deal not only facilitates Baykar's entry into the European market but also revitalizes Piaggio Aerospace, a historic name in Italian aviation, by integrating it into the burgeoning UAS sector.

The collaboration between Baykar and Piaggio Aerospace is expected to leverage the latter's extensive engineering expertise and infrastructure to bolster production and maintenance capabilities for drones like the TB2 and Akinci. With the establishment of a joint venture, LBA Systems, in partnership with Leonardo, Baykar aims to tap into a market projected to reach $100 billion over the next decade. This venture underscores a shared vision for advancing Europe's defense industry through innovation and strategic partnerships.

Employment and industrial growth stand at the heart of this acquisition. Baykar has committed to preserving jobs at Piaggio's Italian facilities and expanding the workforce to meet future production demands. This approach not only safeguards existing employment but also promises to inject new vitality into Italy's aerospace sector. The deal has been hailed by Italian officials as a milestone that could redefine Italy's role in unmanned aviation, highlighting the potential for technological advancement and economic growth.

As Baykar embarks on this new chapter, the focus is on honoring Piaggio Aerospace's legacy while steering it towards future innovations. The acquisition is more than a business transaction; it's a fusion of Turkish ambition with Italian engineering excellence, aimed at shaping the future of aerospace and defense. With plans to enhance the production of the P.180 Avanti EVO and strengthen maintenance services, Baykar is set to propel Piaggio Aerospace into a new era of aerospace innovation and global competitiveness.

Recommended news

Angelina Jolie's 'Couture' Explores Fashion World's Personal Battles

Angelina Jolie made a striking appearance at the Festa del Cinema di Roma, walking the red carpet for the premiere of her new film 'Couture,' which she both stars in and co-produces. The actress chose a dramatic black backless gown that showcased her extensive back tattoos, including a...

Read more


Ranucci's Report to Resume Broadcasts Despite Recent Bombing Incident Near Home

Sigfrido Ranucci, the prominent journalist and host of the investigative program Report, has returned to television following a bombing incident on October 17th near his residence in Pomezia. During an appearance on Monica Maggioni's program "In mezz'ora," Ranucci announced the upcoming...

Read more


Mafia Infiltration in Aeolian Islands Cruise Business Uncovered in Major Asset Confiscation

Italian financial police in Catanzaro have executed a definitive confiscation order for assets valued at over €1.6 million from an individual connected to the Accorinti crime clan of Briatico. The seizure includes a land parcel with an overlying building and ownership shares in a local...

Read more


Pompei's Elite Built Tower Houses to Assert Power, Digital Archaeology Reveals

Archaeological research at the ancient Roman city of Pompei has revealed new evidence suggesting elite residents constructed private towers as symbols of power and wealth before the city's destruction in 79 AD. A collaborative study between the Pompei Archaeological Park and Berlin's Humboldt...

Read more


Breakthrough ADC Therapy Shows Promise Against Aggressive Breast Cancer

Significant advances in the treatment of triple-negative breast cancer (TNBC), one of the most aggressive forms of breast cancer, were highlighted at the European Society for Medical Oncology (ESMO) congress. New data from Phase 3 clinical trials demonstrate that antibody-drug conjugates...

Read more